Skip to main content

Table 1 Characteristics of patients in TDF+PI/r and control groups a

From: Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study

Variable TDF+PI/r group (n=75) Control group (n=75) P
Male 58(77.3) 53(70.7) 0.352
Age (years) 44 (41–50) 42 (34–53) 0.322
Race    0.363
  Han 74 (98.7) 71 (94.7)  
  Other 1 (1.3) 4 (5.3)  
Duration of HIV seropositive (months) 65 (26–139) 22 (19–28) <0.001
Smoking    
  Yes 32(42.7) 27(36.0) 0.403
  No 43(57.3) 48(64.0)  
Hypertension    0.347
  Yes 7(9.3) 4(5.3)  
  No 68(90.7) 71(94.7)  
Diabetes    0.332
  Yes 4(5.3) 1(1.3)  
  No 67(89.3) 68(90.7)  
  Unknown 4(5.3) 6(8.0)  
BMI b (kg/m 2 ) 21.6 (20.1-23.5) 20.6 (19.5-23.0) 0.129
CD4 cell count (cells/μl) 157(63–267) 185 (104–259) 0.509
Viral load (log10 copies/ml) 4.4 (3.7-4.8) 4.5 (3.9-4.9) 0.117
Proteinuria    0.631
  Positive 11(14.7) 9 (12)  
  Negative 64(85.3) 66 (88)  
Serum creatinine (μmol/L) 71(65–81) 71.4(62–81.7) 0.263
eGFR c (ml/min/1.73 m 2 ) 101.6 (85.6-117.2) 105.1 (76.8-110.3) 0.376
  1. Note.
  2. aValues are expressed as median (interquartile range) or number (percentage).
  3. bBMI =weight (kg)/(height (m))2.
  4. ceGFR = 186 × (Serum creatinine (mg/dL))-1.154 × (age(years))-0.203 × (0.742 if female).